Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AVIRthis companyAtea Pharmaceuticals, Inc.	$4.42	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
ABUSArbutus Biopharma Corp	$3.67	-28.29×	12.04×	65.44×	-27.47×	-163.1%	97.4%	-192.1%	-237.9%	-43.7%	-30.3%	-4.3%	0.05×	0.42×	-278.88×	15.73×	0.0%	5	28.57	4	A-
ALGSAligos Therapeutics, Inc.	$4.38	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ASMBAssembly Biosciences, Inc.	$20.95	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
COCPCocrystal Pharma, Inc.	$1.03	-1.26×	1.75×	0×	-0.65×	-55.3%	0.0%	0.0%	0.0%	-139.5%	-115.1%	-74.2%	0.24×	0.65×	0×	3.68×	0.0%	3	-108.13	1	C-
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
Peer median	—	-3.8×	1.84×	5.27×	-5.99×	-163.1%	93.0%	-130.7%	-125.4%	-45.2%	-31.4%	-12.6%	0.1×	0.57×	0×	4.21×	0.0%	3	-0.92	2	—